投资工具 / 美股
Medtronic · MDT
数据仅供参考,不构成投资建议。
投资工具 / 美股
数据仅供参考,不构成投资建议。
| 季度 | 截止日 | 申报日 | 营收 | 营收同比 g | Δg | 推导方式 |
|---|---|---|---|---|---|---|
| 2026Q2 | 2026-07-31 | 2026-09-03 | $9.76B | +13.7% | +3.9pp | 3M |
| 2026Q1 | 2026-04-24 | 2026-06-18 | $9.81B | +9.9% | +1.1pp | FY-9M |
| 2025Q4 | 2026-01-23 | 2026-02-24 | $9.02B | +8.7% | +2.1pp | 3M |
| 2025Q3 | 2025-10-24 | 2025-11-25 | $8.96B | +6.6% | −1.7pp | 3M |
| 2025Q2 | 2025-07-25 | 2026-09-03 | $8.58B | +8.4% | +4.4pp | 3M |
| 2025Q1 | 2025-04-25 | 2026-06-18 | $8.93B | +3.9% | +1.4pp | FY-9M |
| 2024Q4 | 2025-01-24 | 2026-02-24 | $8.29B | +2.5% | −2.7pp | 3M |
| 2024Q3 | 2024-10-25 | 2025-11-25 | $8.4B | +5.2% | +2.5pp | 3M |
口径:单季同比;Δg = 本季 g − 上季 g;按财季映射日历季度;申报日可见。† 不连续点(上年同季营收 ≤0 或 Δg 幅度超过 50pp)。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 季度 | 截止日 | 毛利 | 销货成本 | 毛利率 | 环比 | 同比 | Δ² |
|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-07-31 | 缺口径:GrossProfit 最后申报于 2020-04-24 | $3.42B | 65.0% | −37bp | −3bp | −63bp |
| 2026Q1 | 2026-04-24 | 缺口径:GrossProfit 最后申报于 2020-04-24 | $3.4B | 65.4% | +152bp | +60bp |
| 季度 | 截止日 | 合同负债 | CL g | RPO | RPO g | 账单额 | 账单额 g | RPO 覆盖 |
|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-07-31 | $500M | +13.1% | $400M | 0.0% | $9.76B | +13.8% | 0.0× |
| 2026Q1 | 2026-04-24 | $500M | +12.1% | $400M | +33.3% |
| 季度 | 截止日 | OCF TTM | OCF g | CapEx TTM | CapEx g | FCF TTM | CapEx 密度 | SBC/FCF | SBC/Rev |
|---|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-07-31 | $8.04B | +12.4% | $1.9B | +3.3% | $6.13B | 5.1% | 8.1% | 1.3% |
| 2026Q1 | 2026-04-24 | $7.33B |
| 季度 | 截止日 | 存货 | 存货 g | 营收 g | 剪刀差 | DIO | DIO 同比 |
|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-07-31 | $6.22B | +5.6% | +13.7% | −8.1pp | 166.0 | −13.0 |
| 2026Q1 | 2026-04-24 | $5.95B | +8.7% | +9.9% | −1.2pp | 159.8 |
| 交易日 | 申报日 | 申报人 | 头衔 | 代码 | 股数 | 价格 | 金额 | 10b5-1 |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 | 2026-10-16 | Marinaro Michael | EVP, Pres MedSurg and Americas | S | 10,420 | $96.00 | $1M | ✓ |
口径:修正广度 =(近 30 日上调 − 下调)/(上调 + 下调),样本 < 3 不出;只展示衍生指标,不展示一致预期原值。 · 数据截至 2026-11-16 · 来源:Yahoo Finance / Nasdaq
未覆盖(期权覆盖为 S&P 500 期权持仓前 100 名每日、其余每周轮换)
暂无警报
口径:本股的警报事件历史(含基线);事件保留 90 天。
| +325bp |
| 2025Q4 | 2026-01-23 | 缺口径:GrossProfit 最后申报于 2020-04-24 | $3.26B | 63.8% | −201bp | −265bp | −355bp |
| 2025Q3 | 2025-10-24 | 缺口径:GrossProfit 最后申报于 2020-04-24 | $3.06B | 65.8% | +83bp | +90bp | +100bp |
| 2025Q2 | 2025-07-25 | 缺口径:GrossProfit 最后申报于 2020-04-24 | $3B | 65.0% | +27bp | −10bp | −29bp |
| 2025Q1 | 2025-04-25 | 缺口径:GrossProfit 最后申报于 2020-04-24 | $3.15B | 64.7% | −174bp | +19bp | −69bp |
| 2024Q4 | 2025-01-24 | 缺口径:GrossProfit 最后申报于 2020-04-24 | $2.78B | 66.5% | +154bp | +88bp | +136bp |
| 2024Q3 | 2024-10-25 | 缺口径:GrossProfit 最后申报于 2020-04-24 | $2.95B | 64.9% | −18bp | −48bp | +28bp |
缺口径:毛利(GrossProfit 最后申报于 2020-04-24)
口径:GM = 毛利/营收;毛利缺失时用 营收−销货成本 推导;环比/同比为基点。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| $9.84B |
| +10.4% |
| 0.0× |
| 2025Q4 | 2026-01-23 | $468M | +1.3% | $400M | 0.0% | $9.03B | +9.0% | 0.0× |
| 2025Q3 | 2025-10-24 | $451M | −3.4% | $300M | −25.0% | $8.97B | +6.7% | 0.0× |
| 2025Q2 | 2025-07-25 | $442M | −4.1% | $400M | 0.0% | $8.57B | +8.2% | 0.0× |
| 2025Q1 | 2025-04-25 | $446M | −1.5% | $300M | −40.0% | $8.91B | +3.7% | 0.0× |
| 2024Q4 | 2025-01-24 | $462M | +3.4% | $400M | −20.0% | $8.29B | +2.3% | 0.0× |
| 2024Q3 | 2024-10-25 | $467M | +7.4% | $400M | −20.0% | $8.41B | +5.2% | 0.0× |
口径:g = 同比;账单额 = 营收 + Δ合同负债(同口径);RPO 覆盖 = RPO / TTM 营收。跨口径(总额/仅流动)不比较。 合同负债口径: 总额 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| +4.1% |
| $1.9B |
| +2.4% |
| $5.43B |
| 5.2% |
| 8.4% |
| 1.3% |
| 2025Q4 | 2026-01-23 | $7.29B | −0.1% | $1.88B | +2.7% | $5.41B | 5.3% | 8.4% | 1.3% |
| 2025Q3 | 2025-10-24 | $7.11B | −1.1% | $1.91B | +12.4% | $5.21B | 5.5% | 8.7% | 1.3% |
| 2025Q2 | 2025-07-25 | $7.15B | +3.6% | $1.84B | +5.1% | $5.3B | 5.4% | 8.1% | 1.3% |
| 2025Q1 | 2025-04-25 | $7.04B | +3.8% | $1.86B | +17.1% | $5.19B | 5.5% | 8.3% | 1.3% |
| 2024Q4 | 2025-01-24 | $7.29B | +12.7% | $1.83B | +18.6% | $5.47B | 5.5% | 7.9% | 1.3% |
| 2024Q3 | 2024-10-25 | $7.2B | +29.2% | $1.7B | +11.2% | $5.5B | 5.1% | 7.6% | 1.3% |
口径:TTM = 近四个离散单季之和;FCF = OCF − CapEx;CapEx 密度 = CapEx/营收 TTM;FCF≤0 时 SBC/FCF 不计算。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| +1.0 |
| 2025Q4 | 2026-01-23 | $6.31B | +12.5% | +8.7% | +3.7pp | 176.5 | −7.7 |
| 2025Q3 | 2025-10-24 | $6.16B | +12.4% | +6.6% | +5.7pp | 183.5 | +13.8 |
| 2025Q2 | 2025-07-25 | $5.89B | +8.7% | +8.4% | +0.3pp | 179.0 | +0.0 |
| 2025Q1 | 2025-04-25 | $5.48B | +5.0% | +3.9% | +1.0pp | 158.8 | +2.4 |
| 2024Q4 | 2025-01-24 | $5.61B | −2.0% | +2.5% | −4.5pp | 184.2 | −3.6 |
| 2024Q3 | 2024-10-25 | $5.48B | −4.8% | +5.2% | −10.0pp | 169.7 | −20.5 |
口径:剪刀差 = 存货同比 − 营收同比(pp,正值=存货增速快于营收);DIO = 存货/销货成本 × 91.25 天。 · 数据截至 2026-11-16 · 来源 SEC EDGAR XBRL
| 2026-10-15 |
| 2026-10-16 |
| Martha Geoffrey |
| Chairman and CEO |
| S |
| 50,000 |
| $95.00 |
| $4.75M |
| ✓ |
| 2026-09-16 | 2026-09-17 | KIIL HARRY SKIP | EVP & President Cardiovascular | S | 1,483 | $93.65 | $138.88K |
| 2026-07-08 | 2026-07-09 | Walter Matthew R. | SVP, Chief HR Officer | S | 3,102 | $83.15 | $257.93K | ✓ |
| 2026-06-08 | 2026-06-09 | KIIL HARRY SKIP | EVP & President Cardiovascular | S | 3,961 | $80.44 | $318.62K |
| 2026-06-08 | 2026-06-09 | KIIL HARRY SKIP | EVP & President Cardiovascular | S | 228 | $80.45 | $18.34K |
| 2026-02-19 | 2026-02-26 | KIIL HARRY SKIP | EVP & President Cardiovascular | S | 668 | $97.83 | $65.35K |
| 2026-02-19 | 2026-02-26 | KIIL HARRY SKIP | EVP & President Cardiovascular | S | 1,648 | $97.86 | $161.27K |
| 2026-02-19 | 2026-02-26 | KIIL HARRY SKIP | EVP & President Cardiovascular | S | 385 | $97.82 | $37.66K |
| 2026-02-19 | 2026-02-26 | KIIL HARRY SKIP | EVP & President Cardiovascular | S | 19,255 | $97.77 | $1.88M |
| 2026-02-19 | 2026-02-26 | KIIL HARRY SKIP | EVP & President Cardiovascular | S | 30,568 | $97.66 | $2.99M |
| 2025-11-19 | 2025-11-21 | Smith Gregory L | EVP Global Ops & Supply Chain | S | 24,186 | $101.93 | $2.47M |
| 2025-11-19 | 2025-11-21 | Smith Gregory L | EVP Global Ops & Supply Chain | S | 1,942 | $101.99 | $198.06K |
| 2025-11-19 | 2025-11-21 | Smith Gregory L | EVP Global Ops & Supply Chain | S | 1,995 | $102.03 | $203.55K |
| 2025-11-19 | 2025-11-21 | Smith Gregory L | EVP Global Ops & Supply Chain | S | 825 | $102.04 | $84.18K |
| 2025-11-19 | 2025-11-21 | Smith Gregory L | EVP Global Ops & Supply Chain | S | 227 | $102.05 | $23.17K |
| 2025-11-19 | 2025-11-21 | Smith Gregory L | EVP Global Ops & Supply Chain | S | 325 | $102.06 | $33.17K |
| 2025-11-19 | 2025-11-21 | Smith Gregory L | EVP Global Ops & Supply Chain | S | 500 | $102.08 | $51.04K |
| 2025-09-03 | 2025-09-05 | KIIL HARRY SKIP | EVP & President Cardiovascular | S | 200 | $91.59 | $18.32K |
| 2025-09-03 | 2025-09-05 | KIIL HARRY SKIP | EVP & President Cardiovascular | S | 8,405 | $91.58 | $769.73K |
| 2025-08-25 | 2025-08-25 | Jellison William R | — | P | 2,500 | $92.37 | $230.93K |
| 2025-08-22 | 2025-08-25 | Jellison William R | — | P | 2,500 | $92.73 | $231.83K |
| 2025-01-24 | 2025-01-27 | Wall Brett A. | EVP & Pres Neuroscience | S | 12,437 | $90.00 | $1.12M | ✓ |
| 2025-01-08 | 2025-01-10 | Wall Brett A. | EVP & Pres Neuroscience | S | 3,000 | $80.41 | $241.23K | ✓ |
| 2025-01-08 | 2025-01-10 | Wall Brett A. | EVP & Pres Neuroscience | S | 6,850 | $80.41 | $550.81K | ✓ |
口径:Form 4/4A 公开市场买入(P)与卖出(S),申报人为董事或高管;汇总与集群为近 365 天,明细为最近 40 笔。 · 数据截至 2026-11-16 · 来源:SEC EDGAR Form 4
口径:SI 来自 FINRA(双周结算);SI% 分母 = SEC 封面总股本;借券费为 IBKR 报价(非全市场);卖空占比 = 当日卖空量/总成交量。 · 数据截至 SI 2026-10-30 · Reg SHO 2026-11-16 · 借券 2026-11-11 · 沿用上一版 · 来源:FINRA、IBKR、iBorrowDesk